BeiGene, Ltd. (NASDAQ:BGNE) Receives $233.42 Average Target Price from Brokerages

Shares of BeiGene, Ltd. (NASDAQ:BGNE) have been given a consensus rating of “Moderate Buy” by the seven research firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $241.21.

Several analysts have commented on BGNE shares. Bank of America lowered their price objective on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a report on Tuesday, July 9th. JMP Securities initiated coverage on BeiGene in a research note on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 target price for the company. JPMorgan Chase & Co. upped their price target on BeiGene from $194.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. Finally, Citigroup raised their price objective on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research report on Thursday, August 8th.

BeiGene Price Performance

Shares of BGNE stock opened at $201.99 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98. The firm has a market cap of $19.57 billion, a P/E ratio of -26.68 and a beta of 0.61. The business’s 50 day moving average price is $182.24 and its 200-day moving average price is $164.51. BeiGene has a fifty-two week low of $126.97 and a fifty-two week high of $215.00.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.27) by $1.12. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The business had revenue of $929.20 million for the quarter, compared to the consensus estimate of $810.34 million. During the same period in the previous year, the firm earned ($3.64) EPS. The company’s quarterly revenue was up 56.1% compared to the same quarter last year. On average, equities research analysts anticipate that BeiGene will post -5.13 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Xiaobin Wu sold 4,500 shares of BeiGene stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $200.14, for a total value of $900,630.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, COO Xiaobin Wu sold 4,500 shares of the stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $200.14, for a total transaction of $900,630.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Julia Aijun Wang sold 472 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $143.90, for a total transaction of $67,920.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,999 shares of company stock valued at $2,282,183. 7.43% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BeiGene

Institutional investors have recently modified their holdings of the business. Partners Capital Investment Group LLP purchased a new position in BeiGene in the 4th quarter worth about $2,762,000. Swedbank AB purchased a new position in shares of BeiGene during the first quarter valued at approximately $2,596,000. AIA Group Ltd lifted its position in BeiGene by 38.9% during the first quarter. AIA Group Ltd now owns 18,497 shares of the company’s stock valued at $2,893,000 after purchasing an additional 5,181 shares during the period. M&G Plc purchased a new stake in BeiGene in the first quarter worth approximately $29,649,000. Finally, Van ECK Associates Corp grew its position in BeiGene by 8.9% in the 2nd quarter. Van ECK Associates Corp now owns 95,577 shares of the company’s stock worth $13,636,000 after purchasing an additional 7,816 shares during the period. 48.55% of the stock is owned by hedge funds and other institutional investors.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.